These emerging therapies , Semaglutide , represent a significant advancement in managing type 2 diabetes and potentially associated conditions . These drugs are categorized as GLP-1 receptor agonists , https://ezekielntmn830918.blogpixi.com/41736730/tirzepatide-a-comprehensive-exploration-into-incretin-compounds